A Swiss nursing-home trial just showed THC/CBD oil cutting rescue sedative doses in dementia patients by almost half

Researchers from Geneva University Hospitals and the University of Geneva ran a randomized, double-blind, placebo-controlled crossover trial in 25 residents across five long-term care facilities, average age 83, all with severe dementia. Each patient got eight weeks of a THC:CBD oil in a 1:2 ratio — doses ramped up to as much as 20 mg THC and 40 mg CBD daily — and eight weeks of placebo, separated by a one-week washout, with the order randomized. The results published in Age and Ageing on August 19.

The headline number: 64 as-needed psychotropic medication doses were given during the cannabis arm, versus 153 during placebo — a rate of 0.06 doses per patient per day versus 0.14, roughly a 57% drop in rescue antipsychotics and benzodiazepines used for agitation, anxiety and insomnia. No serious adverse events were tied to the study drug, and six months after the trial ended, 21% of patients who kept taking it had come off their other psychotropic medications entirely.

It's a meaningful result because PRN antipsychotics and benzos are the default tool for dementia-related agitation in long-term care, despite carrying black-box warnings for elevated mortality and stroke risk in exactly this population. A non-opioid, comparatively well-tolerated option that measurably cuts how often staff reach for those rescue doses is worth taking seriously, even from a small trial.

The caveats matter too: 25 patients in one region is not a practice-changing sample, and this builds on the same Geneva research group's earlier feasibility work rather than standing alone. It's also a reminder of the gap between this kind of study and U.S. practice — most American nursing homes still have no clean pathway to formally prescribe and titrate cannabis oil for residents, Schedule III status notwithstanding.